media – Page 185 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

CPhI Korea 2024

Organiser: Informa Markets Time:27 – 29 August 2024 address：513, Yeongdong daero, Gangnam-gu, Seoul Exhibition hall: COEX Product range: Raw materials: Vitamins, hormones, sulfonamides, antipyretic analgesics, tetracycline, amino acids and their derivatives, chloramphenicol, digestive system drugs, other anti-infective drugs, penicillins, aminoglycosides, lincomycin, cardiovascular system drugs, anti-parasitic diseases drugs, cephalosporins, macrolides, respiratory system drugs, central nervous system drugs, other Western medicine raw materials Excipients and dosage forms: excipients, flow AIDS, enteric materials, antioxidants, sweeteners, penetration enhancers, preservatives, disintegrators, coating materials, surfactants, sunshades, flavors, filter AIDS, stabilizers, lubricants, plasticizers, solvents, flavor straighteners, coloring agents, clarifying agents, PH regulators, etc Natural extract: plant extract, animal extract, traditional Chinese medicine raw material, functional food raw material, health care raw material, nutrition and health raw material, supplement, dietary fiber, cosmetic raw material About CPhI Korea ： Seoul Pharmaceutical Raw Materials Exhibition (CPhI Korea) is the largest and most influential pharmaceutical raw materials exhibition in South Korea. In ...
- Source: drugdu
- 178
- March 15, 2024
Weight Loss Industry Market Hit New High in 2023 Due to Weight Loss Drugs and Other Medical Interventions

Mike Hollan The medical side of the market is growing while the commercial side seems to be struggling. A new study reveals just how strong of a year 2023 was for the weight loss drug industry. Anti-obesity medications (AOMs) have seen a surge in popularity over the past year. This is due to a variety of factors, including the increase in demand for drugs like Wegovy and Ozempic. The two drugs became so popular in 2023 that Wegovy’s developer Novo Nordisk had to temporarily limit the supply of lower, beginner doses of the medication. While it’s clear that AOMs had a good year in 2023, a new report details the heights of that success. According to a study conducted Marketdata LLC and published in Research and Markets, the weight loss market in 2023 rose to a historic peak. In a press release,1 Research and Markets explains that the boom in ...
- Source: drugdu
- 113
- March 14, 2024
Trial Shows Lilly’s Lebrikizumab Produces Improvements in Atopic Dermatitis Severity, Particularly in Individuals with Skin of Color

Don Tracy, Associate Editor First of its kind study reported major improvements in skin clarity and itch relief in over two-thirds of participants. New trial data show that 68% of participants with skin of color suffering from moderate-to-severe atopic dermatitis who were administered Eli Lilly’s lebrikizumab experienced at least a 75% reduction in disease severity, including skin clearance and itch relief. The study notes that people with skin of color have faced a lack of representation in previous clinical trials and are more likely to experience severe symptoms of atopic dermatitis and face delays in diagnosis and treatment.1 “People with skin of color are disproportionately affected by atopic dermatitis, often experiencing more severe symptoms, a delay in diagnosis and a lengthier timeframe to find appropriate treatment. They also have been historically underrepresented in clinical trials, which means we have lacked data pertaining to the treatment of patients with skin of ...
- Source: drugdu
- 113
- March 14, 2024
Myopia control drug Xingqimeioupin® is approved for marketing

On March 11, 2024, Sinqi Pharmaceutical Co., Ltd. officially announced that its undependetly developed drug, Xingqi Meioupin® 0.01% Atropine Sulfate Eye Drops indicated for the slowing of the myopia progression in children aged 6 to 12 years from -1.00D to -4.00D (astigmatism ≤1.50D, anisometropia ≤1.50D). Currently, there are no similar products approved for myopia-related indications in China. Xingqi Meioupins® adopts the exclusive MYOSTAFORT® innovative technology, the preparation is more stable, the eye drops are more comfortable, and no preservatives are added, bringing safety, effectiveness, convenience, accessibility and reasonable price to the vast number of myopic children and adolescents in China. In China, there is a high incidence of myopia, low age of onset, and a high proportion of high-grade myopia. Myopia prevention and control has become a national policy. In 2021, the National Health Commission announced: In 2020, our domestic overall myopia rate among children and adolescents was 52.7%, including ...
- Source: drugdu
- 230
- March 14, 2024
NHS campaign urges over 900,000 young adults to catch up on missed MMR vaccine

The NHS has announced it is targeting young adults to catch up on their missed measles, mumps and rubella (MMR) vaccines as part of the NHS catch-up campaign. In England, more than 900,000 adults aged 19 to 25 years will be invited to book an appointment for their missed vaccine. Following on from the national health service’s recent reminder for 200,000 16- to 19-year-olds to receive the MMR vaccine, the NHS campaign will target young adults in areas more at risk: the West Midlands, Greater Manchester and London. MMR are highly infectious illnesses that can lead to blindness, deafness and swelling of the brain. Currently one of the most infectious diseases globally, with no medical treatment available, one adult or child infected with measles can pass the disease on to around 15 other unvaccinated individuals. According to the UK Health Security Agency (UKHSA), between October 2023 and March 2024, approximately ...
- Source: drugdu
- 149
- March 14, 2024
Epic Pharma of Queens to rent a Westbury building from drugmaker P&L Development

A Queens-based drugmaker wants to rent another drugmaker’s Westbury office and warehouse, officials said. Epic Pharma LLC, a manufacturer of generic drugs, would lease 609-2 Cantiague Rock Rd. from the building’s owner, P&L Development LLC, which also produces generic drugs. Epic would occupy “essentially all of the space” in the 105,000-square-foot facility for “warehouse and distribution operations,” along with offices, said P&L president Evan Singer. An Epic executive didn’t respond to requests for comment last week and on Monday. P&L used the Cantiague Rock Road building as a corporate office and warehouse through last December. But the family-owned business no longer needs the space because some of its 575 employees in Nassau County work remotely at least part of the week. “P&L offers employees a hybrid working environment, which lessens the need for such a large corporate office,” Singer said, adding the company has consolidated its operations into other buildings ...
- Source: drugdu
- 169
- March 14, 2024
ICR awarded $25m by Cancer Grand Challenges to research solid tumours in children

Globally, cancer is currently the most leading cause of death due to disease among children The Institute of Cancer Research (ICR) has announced it has been selected to receive a Cancer Grand Challenges (CGC) award of up to $25m to research the challenges of solid tumours in children. First launched in 2020 by Cancer Research UK (CRUK) and the National Cancer Institute (NCI), CGC now brings together 1,200 researchers and 16 teams worldwide to take on 13 of “cancer’s toughest challenges”. Currently the leading cause of death due to disease among children globally, most outcomes for some childhood cancers have not improved in more than three decades. The CGC team PROTECT aims to explore new, less invasive and more targeted treatments for children living with cancers. For the next five years, the PROTECT team, involving experts from the ICR and the Hopp Children’s Cancer Center Heidelberg in Germany, will use ...
- Source: drugdu
- 154
- March 14, 2024
The IND Application of Henlius’ Novel Anti-GARP/TGF-β1 mAb HLX6018 Approved by NMPA

Shanghai, China, Mar 12th, 2024 – Shanghai Henlius Biotech, Inc. (2696.HK) announced the investigational new drug (IND) application for clinical trial of HLX6018，a novel anti-GARP/TGF-β1 monoclonal antibody (mAb) independently developed by the company, was approved by the National Medical Products Administration (NMPA) for the treatment of idiopathic pulmonary fibrosis (IPF). HLX6018 is the first innovative product of Henlius in the treatment field of chronic inflammatory diseases. Currently, no mAb targeting GARP/TGF-β1 has been approved for marketing globally. Fibrosis is a pathological process characterised by persistent tissue scars which attributed to excessive deposition of extracellular matrix (ECM). This condition can be induced by a variety of stimuli such as infections, autoimmune reactions, radiation, and tissue injury. Common fibrosis-related diseases include IPF, non-alcoholic steatohepatitis (NASH)/metabolic dysfunction-associated steatohepatitis (MASH), cirrhosis, chronic kidney disease (CKD), myocardial infarction (MI), etc. Among them, IPF is a chronic, progressive interstitial lung disease with unknown etiology, and was ...
- Source: drugdu
- 198
- March 14, 2024
2024 AACR Outlook | Chiatai Tianqing’s Innovative Drug Anrotinib, TQB2916 (CD40 Agonist) Together with 5 Studies to be Presented on the International Stage

The annual meeting of the American Association for Cancer Research (AACR) will be held on April 5-10, 2024, local time in San Diego, USA. As one of the world’s most influential academic events in the field of oncology, the AACR Annual Meeting focuses on all aspects of oncology research and innovation, and releases cutting-edge research results in the field of global oncology. Recently, AACR officially released the information of selected studies, and five studies of two innovative drugs, namely, Anrotinib (small molecule multi-targeted receptor tyrosine kinase inhibitor) and TQB2916 (CD40 agonist) from Chiatai Tianqing Pharmaceutical Group, have been selected. Clinical Studies ALTER-G-001 A Multicohort, Multicenter, Phase II Study – Cohort C Results Update: Anlotinib in Combination with Chemotherapy for First-Line Treatment of Digestive Tract Tumors with Unresectable Liver Metastases CT213/13 – Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, ...
- Source: drugdu
- 221
- March 14, 2024
FDA Approves Expanded Indication for Praluent to Lower LDL-C in Pediatric Patients with HeFH

Davy James Regeneron’s PCSK9 inhibitor approved to reduce low-density lipoprotein cholesterol in patients 8 years of age and older with heterozygous familial hypercholesterolemia. The FDA has approved an expanded indication for Regeneron’s PCSK9 inhibitor Praluent (alirocumab) to include patients 8 years of age and older for the reduction of low-density lipoprotein cholesterol (LDL-C) in those with heterozygous familial hypercholesterolemia (HeFH).1 In clinical trials, the fully human monoclonal antibody, which binds and inhibits to circulating PCSK9, has been found to lower LDL-C in patients with hyperlipidemia either as a monotherapy or combined with other lipid-lowering therapies (LLTs).2 “Many children with (HeFH) are able to substantially improve their LDL-C (bad cholesterol) with currently available therapies,” said Mary P. McGowan, MD, chief medical officer of the Family Heart Foundation, in a press release. “But for those children whose LDL-C remains dangerously high, this approval is an important milestone as it gives these children ...
- Source: drugdu
- 180
- March 13, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.